Nanox AI Fatty Liver Solution - HealthFLD

Qualitative and quantitative analysis of liver attenuation on contrast and non-contrast chest and abdominal CT scans.

Book a meeting

Overview

Nanox.AI HealthFLD device uses AI processing to analyze organizations’ throughput of chest and abdomen CT scans to Measures liver attenuation (HU), and highlights the result when outside the reference range that can be included in the radiology report, which can then be used to trigger a best practice care recommendations and increase early diagnosis and treatment for patients at high risk.

Nanox-1

Features

  • Measures liver attenuation (HU) and highlights the result when outside the reference range with visualization of measurement location (ROIs).

  • Uses threshold levels adjusted according to contrast enhancement phase.

    o Non-contrast study: preset value of 40 HU

    o Portal venous phase contrast study: preset value of 75 HU

Benefits

  • Uses existing routine medical CT images.
  • Can help identify patients with asymptomatic undetected chronic disease earlier in their patient journey.
  • Potential to increasing revenue due to higher patient retention within the medical system
  • In a study published in AJR, the Nanox.AI liver solution demonstrated enhanced diagnostic accuracy, automation efficiency, scalability across. diverse patient populations, and clinical relevance in detecting moderate hepatic steatosis on postcontrast CT scans. These findings suggest its potential utility in clinical practice for improving the management of nonalcoholic fatty liver disease (NAFLD).¹

Image examples

Nanox FLD

To find out more about this solution or any of the other 140+ applications on the Blackford Platform, please book a discovery call with our team.

review image 1

Book a meeting

We’d welcome the opportunity to learn more about your AI needs and to explain how partnering with Blackford can drive efficiency and provide ongoing value.

Book a Meeting

¹Pickhardt PJ, Blake GM, Kimmel Y, Weinstock E, Shaanan K, Hassid S, et al. Detection of Moderate Hepatic Steatosis on Portal Venous Phase Contrast-Enhanced CT: Evaluation Using an Automated Artificial Intelligence Tool. American Journal of Roentgenology. 2023 Dec 1;221(6):748–58.‌